Advertisement
U.S. markets open in 4 hours 9 minutes
Advertisement

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
6.40-0.33 (-4.90%)
At close: 04:00PM EST
6.43 +0.03 (+0.47%)
Pre-Market: 04:03AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Continuation Wedge (Bearish)

Continuation Wedge (Bearish)

Performance Outlook
Previous Close6.73
Open6.67
Bid6.11 x 4000
Ask6.61 x 4000
Day's Range6.32 - 6.83
52 Week Range3.21 - 9.36
Volume7,213,438
Avg. Volume7,531,987
Market Cap1.638B
Beta (5Y Monthly)0.36
PE Ratio (TTM)N/A
EPS (TTM)-2.08
Earnings DateFeb 26, 2024 - Mar 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.42
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IOVA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Iovance Biotherapeutics, Inc.
    DVAX: What does Argus have to say about DVAX?DYNAVAX TECHNOLOGIES CORP has an Investment Rating of HOLD; a target price of $14.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • Zacks

    Why Is Iovance Biotherapeutics (IOVA) Up 53% Since Last Earnings Report?

    Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Motley Fool

    Why Iovance Biotherapeutics Stock Is Jumping Today

    Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were jumping 10.9% higher as of 11:49 a.m. ET on Monday. The nice gain came after Goldman Sachs initiated coverage on Iovance stock with a buy recommendation. Investors no doubt liked Goldman Sachs' 12-month price target of $12 for Iovance.

  • GlobeNewswire

    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    SAN CARLOS, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on November 16, 2023 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 59,950 shares of Iovance’s common stock to nine new non-executive employees. The awards